Exciting News for the Bone Field: New Osteoporosis Treatment Approved by FDA
Date: May 04, 2017
Last Friday the FDA approved a new anabolic therapy drug, TYMLOSTM (abaloparatide) developed by Radius Health. This is exciting news for the bone field as this is the first new osteoporosis treatment drug approved in over seven years. The FDA's approval of TYMLOS was based on results at 18 months from the landmark ACTIVE trial and first six months of ACTIVExtend trial that demonstrated consistent significant and rapid reductions in the risk of vertebral and nonvertebral fractures regardless of age, years since menopause, presence or absence of prior fracture (vertebral or nonvertebral) and bone mineral density (BMD) at baseline.